| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3738 |
| Trial ID | NCT06231368 |
| Disease | Autoimmune Hemolytic Anemia |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CNCT19|inaticabtagene autoleucel |
| Location approved | China |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | The Safety and Efficacy of CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure of Three or More Lines of Therapy |
| Year | 2024 |
| Country | China |
| Company sponsor | Institute of Hematology & Blood Diseases Hospital, China |
| Other ID(s) | HY001010 |
| Cohort 1 | |||||||||
|
|||||||||